All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?
Featured:
Tycel PhillipsDuring the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Tycel Phillips, University of Michigan, Ann Arbor, US. We asked, Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in mantle cell lymphoma (MCL)?
Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?
To answer this question, Phillips describes a phase I trial investigating complete response rate and minimal residual disease (MRD) detectability when using this triplet regimen in untreated patients with MCL.
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?